MD-PREVAILION
19.10.2020 13:02:07 CEST | Business Wire | Press release
Prevailion, a global leader in cyber adversary intelligence, today announced that it has been recognized as a Gartner Cool Vendor in the latest Cool Vendors in Security Operations and Threat Intelligence report.
The Gartner report profiles “emerging vendors that security and risk management leaders should consider when evaluating emerging threats requiring the latest in security operations technologies.” Gartner writes that: “Security and risk management leaders are seeking solutions for better visibility into their IT environments to help strengthen their security posture, as well as prioritize security control gaps and remediation activities based on business risk.” It also notes that: “Organizations struggle to mitigate vulnerabilities because of the inability to prioritize them due to a lack of context about the assets and external threat environment.”*
This lack of visibility into active and emerging threats poses a major challenge to organizational cybersecurity, and is the primary focus of Prevailion. Through a global constellation of clandestine sensors, Prevailion actively monitors thousands of cyber attacks in real-time, including billions of malware communications, providing an unprecedented level of adversary intelligence that companies can use to protect their networks.
“We are honored to be selected by Gartner, which we believe validates the core technology behind our platform and the hard work and dedication of our team,” said Karim Hijazi, founder and CEO of Prevailion. “At Prevailion, we have been charting a new course in the field of threat intelligence, by empowering companies with greater visibility into the threat actors targeting their networks and the networks of their closest partners. By going after the attackers’ own infrastructure, we can provide companies with unprecedented insights into criminal and nation-state hackers’ malicious activity and list of targets. This enables corporate security teams to better prioritize threats, by focusing immediately on confirmed attacks, rather than having to rely on noisy and error-prone security alerts or vague risk scorecards.”
EXCLUSIVE INSIGHTS INTO CYBER THREAT ACTIVITY
Prevailion is currently tracking over 28,000 compromised organizations around the world, ranging from publicly traded companies and their supply chain partners to governments, universities, NGOs and more. Many of the cyber compromises Prevailion has observed are undetected or unreported by the victim organizations.
According to Prevailion’s exclusive intelligence, 22% of the Fortune 500 are showing active or recent compromise activity by criminal or state-affiliated hackers. This includes 79% of software companies and 64% of pharmaceuticals, which are the most heavily targeted industries, based on recent cyber activity.
Prevailion’s unique cyber intelligence capability allows it to detect active compromises inside corporate networks that do not require any access or confirmation by the affected corporation. To do this, Prevailion’s intelligence team targets criminal networks in order to intercept communications between the hackers’ “command-and-control” servers and the malware they’ve deployed. This ability to eavesdrop on criminal activity gives Prevailion significantly enhanced insights into real-time hacking operations taking place all over the world. It also allows them to anticipate new attacks ahead of time.
Prevailion’s APEX Platform is a reliable source of information on thousands of unreported corporate breaches, and provides around-the-clock intelligence on new compromises, escalating breach activity and corporate remediation efforts.
*Gartner “Cool Vendors in Security Operations and Threat Intelligence,” Mitchell Schneider, Ruggero Contu, John Watts, Craig Lawson, October 13, 2020.
GARTNER DISCLAIMER
Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
ABOUT PREVAILION
Prevailion is a compromise intelligence company, transforming the way organizations approach risk mitigation and business decision-making. Through next-level tailored intelligence and a zero-touch platform, Prevailion provides a full view of confirmed “Evidence of Compromise” (EOC) for customers and their partner ecosystems. To learn more about Prevailion, visit www.prevailion.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201019005166/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
